دورية أكاديمية
Rapid development of double-hit mRNA antibody cocktail against orthopoxviruses.
| العنوان: | Rapid development of double-hit mRNA antibody cocktail against orthopoxviruses. |
|---|---|
| المؤلفون: | Chi H; State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, AMMS, 100071, Beijing, China., Zhao SQ; State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, AMMS, 100071, Beijing, China., Chen RY; State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, AMMS, 100071, Beijing, China., Suo XX; State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, AMMS, 100071, Beijing, China.; College of Life Sciences, Inner Mongolia Agricultural University, Hohhot, 010018, Inner Mongolia, China., Zhang RR; State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, AMMS, 100071, Beijing, China., Yang WH; State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, AMMS, 100071, Beijing, China., Zhou DS; State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, AMMS, 100071, Beijing, China., Fang M; School of Life Sciences, Henan University, Kaifeng, 475004, Henan, China., Ying B; Suzhou Abogen Biosciences Co., Ltd, Suzhou, 215123, Jiangsu, China., Deng YQ; State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, AMMS, 100071, Beijing, China. dengyq1977@126.com., Qin CF; State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, AMMS, 100071, Beijing, China. qincf@bmi.ac.cn.; Research Unit of Discovery and Tracing of Natural Focus Diseases, Chinese Academy of Medical Sciences, 100071, Beijing, China. qincf@bmi.ac.cn. |
| المصدر: | Signal transduction and targeted therapy [Signal Transduct Target Ther] 2024 Mar 27; Vol. 9 (1), pp. 69. Date of Electronic Publication: 2024 Mar 27. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101676423 Publication Model: Electronic Cited Medium: Internet ISSN: 2059-3635 (Electronic) Linking ISSN: 20593635 NLM ISO Abbreviation: Signal Transduct Target Ther Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: [London] : Nature Publishing Group, [2016]- |
| مواضيع طبية MeSH: | Orthopoxvirus* , Vaccinia*/prevention & control, Animals ; Mice ; Combined Antibody Therapeutics ; Antibodies, Viral ; Vaccinia virus/genetics |
| مستخلص: | The Orthopoxvirus genus, especially variola virus (VARV), monkeypox virus (MPXV), remains a significant public health threat worldwide. The development of therapeutic antibodies against orthopoxviruses is largely hampered by the high cost of antibody engineering and manufacturing processes. mRNA-encoded antibodies have emerged as a powerful and universal platform for rapid antibody production. Herein, by using the established lipid nanoparticle (LNP)-encapsulated mRNA platform, we constructed four mRNA combinations that encode monoclonal antibodies with broad neutralization activities against orthopoxviruses. In vivo characterization demonstrated that a single intravenous injection of each LNP-encapsulated mRNA antibody in mice resulted in the rapid production of neutralizing antibodies. More importantly, mRNA antibody treatments showed significant protection from weight loss and mortality in the vaccinia virus (VACV) lethal challenge mouse model, and a unique mRNA antibody cocktail, Mix2a, exhibited superior in vivo protection by targeting both intracellular mature virus (IMV)-form and extracellular enveloped virus (EEV)-form viruses. In summary, our results demonstrate the proof-of-concept production of orthopoxvirus antibodies via the LNP-mRNA platform, highlighting the great potential of tailored mRNA antibody combinations as a universal strategy to combat orthopoxvirus as well as other emerging viruses. (© 2024. The Author(s).) |
| References: | Signal Transduct Target Ther. 2023 Apr 28;8(1):172. (PMID: 37117161) Emerg Microbes Infect. 2023 Dec;12(1):2204151. (PMID: 37070521) Cell Res. 2022 Apr;32(4):375-382. (PMID: 35210606) Vaccines (Basel). 2022 Jul 06;10(7):. (PMID: 35891248) Lancet Infect Dis. 2023 Sep;23(9):1042-1050. (PMID: 37336224) New Microbes New Infect. 2023 Mar;52:101102. (PMID: 36815201) Emerg Infect Dis. 2007 Jul;13(7):965-72. (PMID: 18214166) Immunol Cell Biol. 2008 Jan;86(1):80-6. (PMID: 17923850) Nat Commun. 2023 Sep 23;14(1):5948. (PMID: 37741831) PLoS Pathog. 2015 Sep 01;11(9):e1005148. (PMID: 26325270) PLoS Negl Trop Dis. 2018 Jun 21;12(6):e0006581. (PMID: 29927927) Immunol Rev. 2011 Jan;239(1):8-26. (PMID: 21198662) Science. 2020 Jul 24;369(6502):. (PMID: 32703849) Signal Transduct Target Ther. 2022 Sep 16;7(1):323. (PMID: 36114202) Curr Opin Infect Dis. 2008 Apr;21(2):153-6. (PMID: 18317038) PLoS One. 2015 Jul 06;10(7):e0131742. (PMID: 26147658) Cell Res. 2023 May;33(5):407-410. (PMID: 36879038) Proc Natl Acad Sci U S A. 2006 Feb 7;103(6):1882-7. (PMID: 16436502) Emerg Microbes Infect. 2023 Dec;12(1):2192815. (PMID: 36947428) J Transl Med. 2019 Feb 22;17(1):54. (PMID: 30795778) J Pharm Sci. 2021 Aug;110(8):2904-2915. (PMID: 33894207) J Virol. 1985 Nov;56(2):482-8. (PMID: 4057358) Front Immunol. 2021 Aug 10;12:675655. (PMID: 34447370) J Virol. 2013 Jan;87(2):900-11. (PMID: 23135728) Nat Rev Immunol. 2022 Oct;22(10):597-613. (PMID: 36064780) Emerg Microbes Infect. 2023 Dec;12(2):2223669. (PMID: 37288876) Nat Commun. 2023 Sep 22;14(1):5925. (PMID: 37739969) Mol Ther Nucleic Acids. 2022 May 10;28:847-858. (PMID: 35664703) Nature. 2022 Jun;606(7912):15-16. (PMID: 35595996) J Virol. 2007 Sep;81(17):8989-95. (PMID: 17581986) Sci Transl Med. 2023 Oct 4;15(716):eadg3540. (PMID: 37792954) Vaccines (Basel). 2021 Jan 31;9(2):. (PMID: 33572679) Antimicrob Agents Chemother. 2020 Mar 24;64(4):. (PMID: 31932370) Virology. 2002 Jun 5;297(2):172-94. (PMID: 12083817) Travel Med Infect Dis. 2023 Mar-Apr;52:102528. (PMID: 36539022) J Transl Med. 2023 Oct 4;21(1):693. (PMID: 37794448) Viruses. 2022 Aug 27;14(9):. (PMID: 36146705) BMC Med. 2023 May 16;21(1):183. (PMID: 37189197) Virology. 2020 May;544:42-54. (PMID: 32174513) J Immunol. 2005 Nov 15;175(10):6829-36. (PMID: 16272340) J Gen Virol. 2002 May;83(Pt 5):1059-1067. (PMID: 11961260) Cell. 2016 Oct 20;167(3):684-694.e9. (PMID: 27768891) J Med Virol. 2023 May;95(5):e28763. (PMID: 37212313) Int J Infect Dis. 2006 May;10(3):193-201. (PMID: 16564720) Nat Immunol. 2024 Feb;25(2):307-315. (PMID: 38182667) Sci China Life Sci. 2023 Oct;66(10):2329-2341. (PMID: 37300753) Vaccine. 2011 Dec 30;29 Suppl 4:D49-53. (PMID: 22185833) Cell. 2020 Sep 3;182(5):1271-1283.e16. (PMID: 32795413) |
| المشرفين على المادة: | 0 (Combined Antibody Therapeutics) 0 (Antibodies, Viral) |
| تواريخ الأحداث: | Date Created: 20240327 Date Completed: 20240328 Latest Revision: 20240329 |
| رمز التحديث: | 20240329 |
| مُعرف محوري في PubMed: | PMC10966106 |
| DOI: | 10.1038/s41392-024-01766-8 |
| PMID: | 38531869 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 2059-3635 |
|---|---|
| DOI: | 10.1038/s41392-024-01766-8 |